1. Home
  2. LQDA vs EIG Comparison

LQDA vs EIG Comparison

Compare LQDA & EIG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LQDA
  • EIG
  • Stock Information
  • Founded
  • LQDA 2004
  • EIG 2000
  • Country
  • LQDA United States
  • EIG United States
  • Employees
  • LQDA N/A
  • EIG N/A
  • Industry
  • LQDA Biotechnology: Pharmaceutical Preparations
  • EIG Property-Casualty Insurers
  • Sector
  • LQDA Health Care
  • EIG Finance
  • Exchange
  • LQDA Nasdaq
  • EIG Nasdaq
  • Market Cap
  • LQDA 1.3B
  • EIG 1.2B
  • IPO Year
  • LQDA 2018
  • EIG 2007
  • Fundamental
  • Price
  • LQDA $13.17
  • EIG $46.53
  • Analyst Decision
  • LQDA Strong Buy
  • EIG Strong Buy
  • Analyst Count
  • LQDA 9
  • EIG 1
  • Target Price
  • LQDA $27.67
  • EIG $58.00
  • AVG Volume (30 Days)
  • LQDA 3.0M
  • EIG 143.4K
  • Earning Date
  • LQDA 08-06-2025
  • EIG 07-30-2025
  • Dividend Yield
  • LQDA N/A
  • EIG 2.75%
  • EPS Growth
  • LQDA N/A
  • EIG N/A
  • EPS
  • LQDA N/A
  • EIG 4.13
  • Revenue
  • LQDA $14,144,000.00
  • EIG $860,200,000.00
  • Revenue This Year
  • LQDA $185.38
  • EIG N/A
  • Revenue Next Year
  • LQDA $350.95
  • EIG $5.56
  • P/E Ratio
  • LQDA N/A
  • EIG $11.23
  • Revenue Growth
  • LQDA N/A
  • EIG N/A
  • 52 Week Low
  • LQDA $8.26
  • EIG $41.48
  • 52 Week High
  • LQDA $19.41
  • EIG $54.44
  • Technical
  • Relative Strength Index (RSI)
  • LQDA 36.80
  • EIG 38.15
  • Support Level
  • LQDA $13.60
  • EIG $46.27
  • Resistance Level
  • LQDA $14.63
  • EIG $47.52
  • Average True Range (ATR)
  • LQDA 0.96
  • EIG 0.69
  • MACD
  • LQDA -0.40
  • EIG -0.12
  • Stochastic Oscillator
  • LQDA 0.46
  • EIG 10.16

About LQDA Liquidia Corporation

Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also generates revenue from the sale of Treprostinil Injection through an agreement between its subsidiary and the manufacturer.

About EIG Employers Holdings Inc

Employers Holdings Inc is a provider of workers' compensation insurance and services focused on small and mid-sized businesses engaged in low-to-medium hazard industries. Its customers are employers, and the insurance premiums that those employers pay to account for company revenue. Substantially all of the remaining revenue is generated through investments. The company operates exclusively in the United States, and it generates more than half of its business in California. By industry, the company has exposure to restaurants, which account for roughly a fourth of the total premiums the company earns. It operates as a single reportable segment, Insurance Operations, through its wholly owned subsidiaries.

Share on Social Networks: